Loading...

Felix Feng, MD

TitleAssociate Professor
InstitutionUniversity of California San Francisco
DepartmentRadiation Oncology
Address1450 Third St
San Francisco CA 94158
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Zhang Y, Pitchiaya S, Cieslik M, Niknafs YS, Tien JC, Hosono Y, Iyer MK, Yazdani S, Subramaniam S, Shukla SK, Jiang X, Wang L, Liu TY, Uhl M, Gawronski AR, Qiao Y, Xiao L, Dhanasekaran SM, Juckette KM, Kunju LP, Cao X, Patel U, Batish M, Shukla GC, Paulsen MT, Ljungman M, Jiang H, Mehra R, Backofen R, Sahinalp CS, Freier SM, Watt AT, Guo S, Wei JT, Feng F, Malik R, Chinnaiyan AM. Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. Nat Genet. 2018 Jun; 50(6):814-824. PMID: 29808028.
      View in: PubMed
    2. Cooperberg MR, Erho N, Chan JM, Feng F, Fishbane N, Zhao SG, Simko JP, Cowan JE, Lehrer J, Alshalalfa M, Kolisnik T, Chelliserry J, Margrave J, Aranes M, Plessis MD, Buerki C, Tenggara I, Davicioni E, Carroll PR. The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer. Eur Urol. 2018 May 28. PMID: 29853306.
      View in: PubMed
    3. Alshalalfa M, Karnes RJ, Sharma V, Choeurng V, Al-Deen Ashab H, Erho N, Trock BJ, Ross AE, Yousefi K, Tsai HK, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, Spratt DE, Abdollah F, Jenkins RB, Klein EA, Nguyen PL, Dicker AP, Den RB, Davicioni E, Feng F, Lotan TL, Schaeffer EM. Development and validation of a prostate cancer genomic signature that predicts early ADT treatment response following radical prostatectomy. Clin Cancer Res. 2018 May 14. PMID: 29760221.
      View in: PubMed
    4. Okunieff P, Casey-Sawicki K, Lockney NA, Hoppe BS, Enderling H, Pinnix CC, Welsh JW, Krishnan S, Yothers G, Brown JM, Knox SJ, Bristow RG, Spellman PT, Mitin T, Nabavizadeh N, Jaboin J, Manning HC, Feng F, Galbraith SM, Solanki AA, Harkenrider MM, Tuli R, Decker RH, Finkelstein SE, Hsu CC, Ha CS, Jagsi R, Shumway D, Daly M, Wang TJC, FitzGerald TJ, Laurie F, Marshall DT, Raben D, Constine LS, Thomas CR, Kachnic LA. Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. Clin Cancer Res. 2018 Apr 16. PMID: 29661779.
      View in: PubMed
    5. Tran PT, Feng F, Ost P. Live to SABR Another Day? Int J Radiat Oncol Biol Phys. 2018 Apr 01; 100(5):1097. PMID: 29722652.
      View in: PubMed
    6. Vasudevan HN, Braunstein SE, Phillips JJ, Pekmezci M, Tomlin BA, Wu A, Reis GF, Magill ST, Zhang J, Feng F, Nicholaides T, Chang SM, Sneed PK, McDermott MW, Berger MS, Perry A, Raleigh DR. Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation. Cell Rep. 2018 Mar 27; 22(13):3672-3683. PMID: 29590631.
      View in: PubMed
    7. Jagsi R, Griffith KA, Bellon JR, Woodward WA, Horton JK, Ho A, Feng F, Speers C, Overmoyer B, Sabel M, Schott AF, Pierce L. Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study. J Clin Oncol. 2018 Mar 20; JCO2017772665. PMID: 29558281.
      View in: PubMed
    8. Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, Den RB, Martin NE, Mouw KW, Orio PF, Choueiri TK, Taplin ME, Trinh QD, Feng F, Nguyen PL. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. 2018 Feb 22. PMID: 29478736.
      View in: PubMed
    9. Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, Zaslavsky A, Chung JS, Smith DC, Karnes RJ, Chang SL, Feng F, Palapattu GS, Taichman RS, Chinnaiyan AM, Tomlins SA, Morgan TM. Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res. 2018 Apr; 16(4):643-654. PMID: 29453313.
      View in: PubMed
    10. Dess RT, Devasia TP, Aghdam N, Jackson WC, Soni PD, Smith CP, Mitchell AL, Suy S, Hamstra DA, Jolly S, Nguyen PL, Feng F, Schipper MJ, Skolarus TA, Miller DC, Wittmann DA, Collins SP, Spratt DE. Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 Jan 31. PMID: 29487023.
      View in: PubMed
    11. Jackson WC, Suresh K, Tumati V, Allen SG, Dess RT, Salami SS, George A, Kaffenberger SD, Miller DC, Hearn JWD, Jolly S, Mehra R, Hollenbeck BK, Palapattu GS, Schipper M, Feng F, Morgan TM, Desai NB, Spratt DE. Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. Eur Urol. 2018 Jan 03. PMID: 29306514.
      View in: PubMed
    12. Moraes FY, Leite ETT, Hamstra DA, Feng F, Arruda FF, Gadia R, Abreu CECV, Marta GN, Hanna SA, Silva JLFD, Carvalho HA, Spratt DE. Self-reported Conflicts of Interest and Trial Sponsorship of Clinical Trials in Prostate Cancer Involving Radiotherapy. Am J Clin Oncol. 2018 Jan; 41(1):6-12. PMID: 26703812.
      View in: PubMed
    13. Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, Knudsen KE, Stadler WM, Feng F, Chinnaiyan AM. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018 Apr 01; 36(10):991-999. PMID: 29261439.
      View in: PubMed
    14. Hosono Y, Niknafs YS, Prensner JR, Iyer MK, Dhanasekaran SM, Mehra R, Pitchiaya S, Tien J, Escara-Wilke J, Poliakov A, Chu SC, Saleh S, Sankar K, Su F, Guo S, Qiao Y, Freier SM, Bui HH, Cao X, Malik R, Johnson TM, Beer DG, Feng F, Zhou W, Chinnaiyan AM. Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. Cell. 2017 Dec 14; 171(7):1559-1572.e20. PMID: 29245011.
      View in: PubMed
    15. Mahal BA, Chen YW, Sethi RV, Padilla OA, Yang DD, Chavez J, Muralidhar V, Hu JC, Feng F, Hoffman KE, Martin NE, Spratt DE, Yu JB, Orio PF, Nguyen PL. Travel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer. 2018 Mar 15; 124(6):1141-1149. PMID: 29231964.
      View in: PubMed
    16. McNair C, Xu K, Mandigo AC, Benelli M, Leiby B, Rodrigues D, Lindberg J, Gronberg H, Crespo M, De Laere B, Dirix L, Visakorpi T, Li F, Feng F, de Bono J, Demichelis F, Rubin MA, Brown M, Knudsen KE. Differential impact of RB status on E2F1 reprogramming in human cancer. J Clin Invest. 2018 Jan 02; 128(1):341-358. PMID: 29202480.
      View in: PubMed
    17. Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. J Natl Cancer Inst. 2017 Dec 01; 109(12). PMID: 29206995.
      View in: PubMed
    18. Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng F. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017 12 01; 3(12):1663-1672. PMID: 28494073.
      View in: PubMed
    19. Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng F, Nguyen PL. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. J Clin Oncol. 2018 Feb 20; 36(6):581-590. PMID: 29185869.
      View in: PubMed
    20. Spratt DE, Dess RT, Feng F. Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.06.027: Salvage Radiotherapy and Hormone Therapy: Change Is Coming, Just Not Quite Yet. Eur Urol. 2017 Oct 27. PMID: 29111144.
      View in: PubMed
    21. Hovelson DH, Liu CJ, Wang Y, Kang Q, Henderson J, Gursky A, Brockman S, Ramnath N, Krauss JC, Talpaz M, Kandarpa M, Chugh R, Tuck M, Herman K, Grasso CS, Quist MJ, Feng F, Haakenson C, Langmore J, Kamberov E, Tesmer T, Husain H, Lonigro RJ, Robinson D, Smith DC, Alva AS, Hussain MH, Chinnaiyan AM, Tewari M, Mills RE, Morgan TM, Tomlins SA. Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. Oncotarget. 2017 Oct 27; 8(52):89848-89866. PMID: 29163793.
      View in: PubMed
    22. Liang Y, Ahmed M, Guo H, Soares F, Hua JT, Gao S, Lu C, Poon C, Han W, Langstein J, Ekram MB, Li B, Davicioni E, Takhar M, Erho N, Karnes RJ, Chadwick D, van der Kwast T, Boutros PC, Arrowsmith CH, Feng F, Joshua AM, Zoubeidi A, Cai C, He HH. LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. Cancer Res. 2017 10 15; 77(20):5479-5490. PMID: 28916652.
      View in: PubMed
    23. Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, Feng F, Spratt DE, Goodrich DW, Eng KH, Ellis L. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. Clin Cancer Res. 2017 Nov 15; 23(22):7072-7083. PMID: 28899973.
      View in: PubMed
    24. Shen MY, Chen JF, Luo CH, Lee S, Li CH, Yang YL, Tsai YH, Ho BC, Bao LR, Lee TJ, Jan YJ, Zhu YZ, Cheng S, Feng F, Chen P, Hou S, Agopian V, Hsiao YS, Tseng HR, Posadas EM, Yu HH. Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection. Adv Healthc Mater. 2018 Feb; 7(3). PMID: 28892262.
      View in: PubMed
    25. Speers C, Zhao SG, Chandler B, Liu M, Wilder-Romans K, Olsen E, Nyati S, Ritter C, Alluri PG, Kothari V, Hayes DF, Lawrence TS, Spratt DE, Wahl DR, Pierce LJ, Feng F. Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. NPJ Breast Cancer. 2017; 3:29. PMID: 28840192.
      View in: PubMed
    26. Dess RT, Hartman HE, Aghdam N, Jackson WC, Soni PD, Abugharib AE, Suy S, Desai NB, Zumsteg ZS, Mehra R, Morgan TM, Feng F, Hamstra DA, Schipper MJ, Collins SP, Spratt DE. Erectile function after stereotactic body radiotherapy for localized prostate cancer. BJU Int. 2018 01; 121(1):61-68. PMID: 28710895.
      View in: PubMed
    27. Jackson WC, Dess RT, Litzenberg DW, Li P, Schipper M, Rosenthal SA, Chang GC, Horwitz EM, Price RA, Michalski JM, Gay HA, Wei JT, Feng M, Feng F, Sandler HM, Wallace RE, Spratt DE, Hamstra DA. A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life. Pract Radiat Oncol. 2018 Jan - Feb; 8(1):40-47. PMID: 29304991.
      View in: PubMed
    28. Green M, Feng F, Mehra R, Spratt DE. Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities. Immunotherapy. 2017 Aug; 9(9):695-699. PMID: 28771102.
      View in: PubMed
    29. Son CH, Hamstra DA, Feng F, Liauw SL. High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir =0.2 to Select Men for Short-term Hormonal Therapy. Am J Clin Oncol. 2017 Aug; 40(4):348-352. PMID: 25436827.
      View in: PubMed
    30. Yin Y, Li R, Xu K, Ding S, Li J, Baek G, Ramanand SG, Ding S, Liu Z, Gao Y, Kanchwala MS, Li X, Hutchinson R, Liu X, Woldu SL, Xing C, Desai NB, Feng F, Burma S, de Bono JS, Dehm SM, Mani RS, Chen BPC, Raj GV. Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation. Cancer Res. 2017 09 15; 77(18):4745-4754. PMID: 28754673.
      View in: PubMed
    31. Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng F. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol. 2018 Feb; 73(2):156-165. PMID: 28716370.
      View in: PubMed
    32. Dess RT, Morgan TM, Nguyen PL, Mehra R, Sandler HM, Feng F, Spratt DE. Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer. Curr Urol Rep. 2017 Jul; 18(7):55. PMID: 28589403.
      View in: PubMed
    33. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 Feb; 73(2):178-211. PMID: 28655541.
      View in: PubMed
    34. Yang DD, Mahal BA, Muralidhar V, Nezolosky MD, Vastola ME, Labe SA, Boldbaatar N, King MT, Martin NE, Orio PF, Beard CJ, Hoffman KE, Trinh QD, Spratt DE, Feng F, Nguyen PL. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer. Eur Urol Focus. 2017 Jun 17. PMID: 28753811.
      View in: PubMed
    35. Aggarwal RR, Feng F, Small EJ. Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications. Oncology (Williston Park). 2017 06 15; 31(6):467-74. PMID: 28620903.
      View in: PubMed
    36. Fei T, Chen Y, Xiao T, Li W, Cato L, Zhang P, Cotter MB, Bowden M, Lis RT, Zhao SG, Wu Q, Feng F, Loda M, He HH, Liu XS, Brown M. Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. Proc Natl Acad Sci U S A. 2017 06 27; 114(26):E5207-E5215. PMID: 28611215.
      View in: PubMed
    37. Hall WA, Bergom C, Thompson RF, Baschnagel AM, Vijayakumar S, Willers H, Li XA, Schultz CJ, Wilson GD, West CML, Capala J, Coleman CN, Torres-Roca JF, Weidhaas J, Feng F. Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. Int J Radiat Oncol Biol Phys. 2017 Jun 09. PMID: 28964588.
      View in: PubMed
    38. Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng F, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Rep. 2017 06 06; 19(10):2045-2059. PMID: 28591577.
      View in: PubMed
    39. Yang DD, Muralidhar V, Mahal BA, Nezolosky MD, Labe SA, Vastola ME, Boldbaatar N, King MT, Martin NE, Orio PF, Choueiri TK, Trinh QD, Den RB, Spratt DE, Hoffman KE, Feng F, Nguyen PL. Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urol Oncol. 2017 Sep; 35(9):542.e25-542.e32. PMID: 28533151.
      View in: PubMed
    40. Nguyen PL, Haddad Z, Ross AE, Martin NE, Deheshi S, Lam LLC, Chelliserry J, Tosoian JJ, Lotan TL, Spratt DE, Stoyanova RS, Punnen S, Ong K, Buerki C, Aranes M, Kolisnik T, Margrave J, Yousefi K, Choeurng V, Davicioni E, Trock BJ, Kane CJ, Pollack A, Davis JW, Feng F, Klein EA. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. Eur Urol. 2017 Nov; 72(5):845-852. PMID: 28528811.
      View in: PubMed
    41. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2017 Dec; 58(12):1956-1961. PMID: 28522741.
      View in: PubMed
    42. Abugharib AE, Dess RT, Soni PD, Narayana V, Evans C, Gaber MS, Feng F, McLaughlin PW, Spratt DE. External beam radiation therapy with or without low-dose-rate brachytherapy: Analysis of favorable and unfavorable intermediate-risk prostate cancer patients. Brachytherapy. 2017 Jul - Aug; 16(4):782-789. PMID: 28499487.
      View in: PubMed
    43. Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A, Small EJ, Feng F. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discov. 2017 09; 7(9):999-1005. PMID: 28450426.
      View in: PubMed
    44. Sinha S, Muralidhar V, Feng F, Nguyen PL. Characteristics and national trends of patients receiving treatment of the primary tumor for metastatic prostate cancer. Prostate Int. 2017 Sep; 5(3):89-94. PMID: 28828351.
      View in: PubMed
    45. Spratt DE, Yousefi K, Deheshi S, Ross AE, Den RB, Schaeffer EM, Trock BJ, Zhang J, Glass AG, Dicker AP, Abdollah F, Zhao SG, Lam LLC, du Plessis M, Choeurng V, Haddad Z, Buerki C, Davicioni E, Weinmann S, Freedland SJ, Klein EA, Karnes RJ, Feng F. Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. J Clin Oncol. 2017 Jun 20; 35(18):1991-1998. PMID: 28358655.
      View in: PubMed
    46. Jackson WC, Desai NB, Abugharib AE, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Folkert M, Laine A, Hannan R, Zumsteg ZS, Sandler H, Hamstra DA, Montgomery JS, Miller DC, Kozminski MA, Hollenbeck BK, Hearn JW, Palapattu G, Tomlins SA, Mehra R, Morgan TM, Feng F, Spratt DE. Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. BJU Int. 2017 09; 120(3):351-357. PMID: 28139024.
      View in: PubMed
    47. Yang DD, Muralidhar V, Mahal BA, Labe SA, Nezolosky MD, Vastola ME, King MT, Martin NE, Orio PF, Choueiri TK, Trinh QD, Spratt DE, Hoffman KE, Feng F, Nguyen PL. National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):338-343. PMID: 28463152.
      View in: PubMed
    48. Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng F, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med. 2017 02 02; 376(5):417-428. PMID: 28146658.
      View in: PubMed
    49. Wahl DR, Nguyen PL, Santiago M, Yousefi K, Davicioni E, Shumway DA, Speers C, Mehra R, Feng F, Osborne JR, Spratt DE. Pan-Cancer Analysis of Genomic Sequencing Among the Elderly. Int J Radiat Oncol Biol Phys. 2017 07 15; 98(4):726-732. PMID: 28258894.
      View in: PubMed
    50. Das R, Gregory PA, Fernandes RC, Denis I, Wang Q, Townley SL, Zhao SG, Hanson AR, Pickering MA, Armstrong HK, Lokman NA, Ebrahimie E, Davicioni E, Jenkins RB, Karnes RJ, Ross AE, Den RB, Klein EA, Chi KN, Ramshaw HS, Williams ED, Zoubeidi A, Goodall GJ, Feng F, Butler LM, Tilley WD, Selth LA. MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. Cancer Res. 2017 02 15; 77(4):1021-1034. PMID: 28011622.
      View in: PubMed
    51. Dess RT, Jackson WC, Suy S, Soni PD, Lee JY, Abugharib AE, Zumsteg ZS, Feng F, Hamstra DA, Collins SP, Spratt DE. Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. Cancer. 2017 05 01; 123(9):1635-1642. PMID: 28001303.
      View in: PubMed
    52. Tan M, Xu J, Siddiqui J, Feng F, Sun Y. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis. Mol Cancer. 2016 12 12; 15(1):81. PMID: 27955654.
      View in: PubMed
    53. Wahl DR, Dresser J, Wilder-Romans K, Parsels JD, Zhao SG, Davis M, Zhao L, Kachman M, Wernisch S, Burant CF, Morgan MA, Feng F, Speers C, Lyssiotis CA, Lawrence TS. Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis. Cancer Res. 2017 02 15; 77(4):960-970. PMID: 27923831.
      View in: PubMed
    54. Thangavel C, Boopathi E, Liu Y, Haber A, Ertel A, Bhardwaj A, Addya S, Williams N, Ciment SJ, Cotzia P, Dean JL, Snook A, McNair C, Price M, Hernandez JR, Zhao SG, Birbe R, McCarthy JB, Turley EA, Pienta KJ, Feng F, Dicker AP, Knudsen KE, Den RB. RB Loss Promotes Prostate Cancer Metastasis. Cancer Res. 2017 02 15; 77(4):982-995. PMID: 27923835.
      View in: PubMed
    55. Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, Cooperberg MR, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Den RB, Nguyen PL, Feng F. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol. 2016 Nov; 17(11):1612-1620. PMID: 27743920.
      View in: PubMed
    56. Shukla S, Evans JR, Malik R, Feng F, Dhanasekaran SM, Cao X, Chen G, Beer DG, Jiang H, Chinnaiyan AM. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. J Natl Cancer Inst. 2017 01; 109(1). PMID: 27707839.
      View in: PubMed
    57. Kim H, Alshalalfa M, Hoffman-Censits J, Lallas CD, Davicioni E, Lin J, Birbe R, Erho N, Lehrer J, Ashab HA, Takhar M, Olson A, Lam LL, Kelly WK, Knudsen KE, Thangavel C, Seiler R, Feng F, Schaeffer EM, Trabulsi EJ, Gomella LG, Hurwitz MD, Dicker AP, Den RB. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. Urol Case Rep. 2016 Nov; 9:51-54. PMID: 27713863.
      View in: PubMed
    58. Niknafs YS, Han S, Ma T, Speers C, Zhang C, Wilder-Romans K, Iyer MK, Pitchiaya S, Malik R, Hosono Y, Prensner JR, Poliakov A, Singhal U, Xiao L, Kregel S, Siebenaler RF, Zhao SG, Uhl M, Gawronski A, Hayes DF, Pierce LJ, Cao X, Collins C, Backofen R, Sahinalp CS, Rae JM, Chinnaiyan AM, Feng F. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun. 2016 Sep 26; 7:12791. PMID: 27666543.
      View in: PubMed
    59. Hall WA, Lawton CA, Jani AB, Pollack A, Feng F. Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy. Semin Radiat Oncol. 2017 Jan; 27(1):11-20. PMID: 27986207.
      View in: PubMed
    60. Abugharib A, Jackson WC, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Zumsteg ZS, Mehra R, Feng F, Morgan TM, Desai N, Spratt DE. Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. J Urol. 2017 Mar; 197(3 Pt 1):662-668. PMID: 27614333.
      View in: PubMed
    61. Pisansky TM, Agrawal S, Hamstra DA, Koontz BF, Liauw SL, Efstathiou JA, Michalski JM, Feng F, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ, Tendulkar RD. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):1046-1053. PMID: 27745980.
      View in: PubMed
    62. Guo H, Ahmed M, Zhang F, Yao CQ, Li S, Liang Y, Hua J, Soares F, Sun Y, Langstein J, Li Y, Poon C, Bailey SD, Desai K, Fei T, Li Q, Sendorek DH, Fraser M, Prensner JR, Pugh TJ, Pomerantz M, Bristow RG, Lupien M, Feng F, Boutros PC, Freedman ML, Walsh MJ, He HH. Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nat Genet. 2016 10; 48(10):1142-50. PMID: 27526323.
      View in: PubMed
    63. Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng F, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol. 2016 Aug 15. PMID: 27528718.
      View in: PubMed
    64. Chen YW, Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Choueiri TK, Hoffman KE, Martin NE, Orio PF, Sweeney CJ, Feng F, Trinh QD, Nguyen PL. Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy. 2016 Nov - Dec; 15(6):695-700. PMID: 27528590.
      View in: PubMed
    65. Lee JY, Daignault-Newton S, Heath G, Scarlett S, Sanda MG, Chang P, Regan MM, Michalski JM, Sandler HM, Feng F, Kuban DA, Zietman AL, Ciezki JP, Kaplan ID, Crociani C, McLaughlin WP, Mantz CA, Finkelstein SE, Suy S, Collins SP, Garin O, Ferrer M, Hamstra DA, Spratt DE. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. Int J Radiat Oncol Biol Phys. 2016 11 15; 96(4):770-777. PMID: 27663760.
      View in: PubMed
    66. Shukla S, Zhang X, Niknafs YS, Xiao L, Mehra R, Cieslik M, Ross A, Schaeffer E, Malik B, Guo S, Freier SM, Bui HH, Siddiqui J, Jing X, Cao X, Dhanasekaran SM, Feng F, Chinnaiyan AM, Malik R. Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. Neoplasia. 2016 08; 18(8):489-99. PMID: 27566105; PMCID: PMC5018094.
    67. Evans JR, Feng F, Chinnaiyan AM. The bright side of dark matter: lncRNAs in cancer. J Clin Invest. 2016 Aug 01; 126(8):2775-82. PMID: 27479746; PMCID: PMC4966302 [Available on 08/01/17].
    68. Spratt DE, Chan T, Waldron L, Speers C, Feng F, Ogunwobi OO, Osborne JR. Racial/Ethnic Disparities in Genomic Sequencing. JAMA Oncol. 2016 Aug 01; 2(8):1070-4. PMID: 27366979.
      View in: PubMed
    69. Mahal BA, Chen YW, Muralidhar V, Mahal AR, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng F, Kim SP, Beard CJ, Martin NE, Trinh QD, Nguyen PL. National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers? Cancer. 2016 Nov 15; 122(21):3371-3377. PMID: 27434225.
      View in: PubMed
    70. Jackson WC, Schipper MJ, Feng F. Reply to Yu-Wen Hu's Letter to the Editor re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol 2016;69:50-7. Eur Urol. 2016 12; 70(6):e159. PMID: 27210457.
      View in: PubMed
    71. Malik B, Feng F. Long noncoding RNAs in prostate cancer: overview and clinical implications. Asian J Androl. 2016 Jul-Aug; 18(4):568-74. PMID: 27072044; PMCID: PMC4955180.
    72. Spratt DE, Zumsteg ZS, Feng F, Tomlins SA. Translational and clinical implications of the genetic landscape of prostate cancer. Nat Rev Clin Oncol. 2016 10; 13(10):597-610. PMID: 27245282.
      View in: PubMed
    73. Speers C, Zhao SG, Kothari V, Santola A, Liu M, Wilder-Romans K, Evans J, Batra N, Bartelink H, Hayes DF, Lawrence TS, Brown PH, Pierce LJ, Feng F. Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer. Clin Cancer Res. 2016 Dec 01; 22(23):5864-5875. PMID: 27225691.
      View in: PubMed
    74. Sapir E, Tao Y, Feng F, Samuels S, El Naqa I, Murdoch-Kinch CA, Feng M, Schipper M, Eisbruch A. Predictors of Dysgeusia in Patients With Oropharyngeal Cancer Treated With Chemotherapy and Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 10 01; 96(2):354-361. PMID: 27473816.
      View in: PubMed
    75. Kozminski MA, Tomlins S, Cole A, Singhal U, Lu L, Skolarus TA, Palapattu GS, Montgomery JS, Weizer AZ, Mehra R, Hollenbeck BK, Miller DC, He C, Feng F, Morgan TM. Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. Urol Oncol. 2016 09; 34(9):415.e1-6. PMID: 27140065.
      View in: PubMed
    76. Spratt DE, Cole AI, Palapattu GS, Weizer AZ, Jackson WC, Montgomery JS, Dess RT, Zhao SG, Lee JY, Wu A, Kunju LP, Talmich E, Miller DC, Hollenbeck BK, Tomlins SA, Feng F, Mehra R, Morgan TM. Independent surgical validation of the new prostate cancer grade-grouping system. BJU Int. 2016 Nov; 118(5):763-769. PMID: 27009882.
      View in: PubMed
    77. Muralidhar V, Catalano PJ, Reznor G, Mahal BA, Choueiri TK, Sweeney CJ, Martin NE, Beard CJ, Chen YW, Nezolosky MD, Hoffman KE, Feng F, Trinh QD, Nguyen PL. Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. J Natl Compr Canc Netw. 2016 Apr; 14(4):421-8. PMID: 27059190.
      View in: PubMed
    78. Vainshtein JM, Schipper M, Vance S, Feng F, Olson KB, Hamstra DA. Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) Prognostic Tool for Prediction of Metastases and Prostate Cancer-specific Mortality in Patients Treated With External Beam Radiation Therapy. Am J Clin Oncol. 2016 Apr; 39(2):173-80. PMID: 24487421.
      View in: PubMed
    79. Spratt DE, Chen YW, Mahal BA, Osborne JR, Zhao SG, Morgan TM, Palapattu G, Feng F, Nguyen PL. Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. Eur Urol Focus. 2016 Dec; 2(5):532-539. PMID: 28723519.
      View in: PubMed
    80. Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA, Den RB, Dicker AP, Karnes RJ, Yu X, Nguyen PL, Rubin MA, de Bono J, Knudsen KE, Davicioni E, Feng F. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. JAMA Oncol. 2016 Apr; 2(4):471-80. PMID: 26746117.
      View in: PubMed
    81. Feng F, Zhang Y, Kothari V, Evans JR, Jackson WC, Chen W, Johnson SB, Luczak C, Wang S, Hamstra DA. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. Neoplasia. 2016 04; 18(4):213-22. PMID: 27108384; PMCID: PMC4840291.
    82. Mahal BA, Chen YW, Efstathiou JA, Muralidhar V, Hoffman KE, Yu JB, Feng F, Beard CJ, Martin NE, Orio PF, Nguyen PL. National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer. 2016 05 15; 122(10):1505-12. PMID: 26970022.
      View in: PubMed
    83. Muralidhar V, Xiang M, Orio PF, Martin NE, Beard CJ, Feng F, Hoffman KE, Nguyen PL. Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. J Contemp Brachytherapy. 2016 Feb; 8(1):1-6. PMID: 26985191; PMCID: PMC4793071.
    84. Cole AI, Morgan TM, Spratt DE, Palapattu GS, He C, Tomlins SA, Weizer AZ, Feng F, Wu A, Siddiqui J, Chinnaiyan AM, Montgomery JS, Kunju LP, Miller DC, Hollenbeck BK, Wei JT, Mehra R. Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. J Urol. 2016 Aug; 196(2):405-11. PMID: 26920466.
      View in: PubMed
    85. Bakkar A, Alshalalfa M, Petersen LF, Abou-Ouf H, Al-Mami A, Hegazy SA, Feng F, Alhajj R, Bijian K, Alaoui-Jamali MA, Bismar TA. microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients. Mol Biol Rep. 2016 Apr; 43(4):229-40. PMID: 26907180.
      View in: PubMed
    86. Freedland SJ, Choeurng V, Howard L, De Hoedt A, du Plessis M, Yousefi K, Lam LL, Buerki C, Ra S, Robbins B, Trabulsi EJ, Shah NL, Abdollah F, Feng F, Davicioni E, Dicker AP, Karnes RJ, Den RB. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. Eur Urol. 2016 10; 70(4):588-596. PMID: 26806658.
      View in: PubMed
    87. Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng F, Chinnaiyan AM. BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. Mol Cancer Res. 2016 04; 14(4):324-31. PMID: 26792867.
      View in: PubMed
    88. Feng F, Kothari V. Driven to metastasize: Kinases as potential therapeutic targets in prostate cancer. Proc Natl Acad Sci U S A. 2016 Jan 19; 113(3):473-5. PMID: 26747602; PMCID: PMC4725536.
    89. Qiao Y, Feng F, Wang Y, Cao X, Han S, Wilder-Romans K, Navone NM, Logothetis C, Taichman RS, Keller ET, Palapattu GS, Alva AS, Smith DC, Tomlins SA, Chinnaiyan AM, Morgan TM. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Neoplasia. 2016 Jan; 18(1):1-9. PMID: 26806347; PMCID: PMC4735600.
    90. Mehra R, Udager AM, Ahearn TU, Cao X, Feng F, Loda M, Petimar JS, Kantoff P, Mucci LA, Chinnaiyan AM. Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. Eur Urol. 2016 10; 70(4):549-552. PMID: 26724257.
      View in: PubMed
    91. McDaniel AS, Hovelson DH, Cani AK, Liu CJ, Zhai Y, Zhang Y, Weizer AZ, Mehra R, Feng F, Alva AS, Morgan TM, Montgomery JS, Siddiqui J, Sadis S, Bandla S, Williams PD, Cho KR, Rhodes DR, Tomlins SA. Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy. Cancer Res. 2015 Dec 15; 75(24):5219-27. PMID: 26670561.
      View in: PubMed
    92. Chen YW, Mahal BA, Muralidhar V, Nezolosky M, Beard CJ, Den RB, Feng F, Hoffman KE, Martin NE, Orio PF, Nguyen PL. Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):683-90. PMID: 26972640.
      View in: PubMed
    93. Jackson WC, Feng F, Daignault S, Hussain M, Smith D, Cooney K, Pienta K, Jolly S, Hollenbeck B, Olson KB, Sandler HM, Ray ME, Hamstra DA. A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy. Adv Radiat Oncol. 2016 Jan-Mar; 1(1):59-66. PMID: 28799570.
      View in: PubMed
    94. Zhao SG, Evans JR, Kothari V, Sun G, Larm A, Mondine V, Schaeffer EM, Ross AE, Klein EA, Den RB, Dicker AP, Karnes RJ, Erho N, Nguyen PL, Davicioni E, Feng F. The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. Clin Cancer Res. 2016 Apr 01; 22(7):1777-86. PMID: 26631616.
      View in: PubMed
    95. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng F, Chinnaiyan AM, Hall E, de Bono JS. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015 Oct 29; 373(18):1697-708. PMID: 26510020.
      View in: PubMed
    96. Zhao SG, Alexander NB, Djuric Z, Zhou J, Tao Y, Schipper M, Feng F, Eisbruch A, Worden FP, Strath SJ, Jolly S. Maintaining physical activity during head and neck cancer treatment: Results of a pilot controlled trial. Head Neck. 2016 Apr; 38 Suppl 1:E1086-96. PMID: 26445898.
      View in: PubMed
    97. Magers MJ, Zhan T, Udager AM, Wei JT, Tomlins SA, Wu AJ, Kunju LP, Lew M, Feng F, Hamstra DA, Siddiqui J, Chinnaiyan AM, Montgomery JS, Weizer AZ, Morgan TM, Hollenbeck BK, Miller DC, Palapattu GS, Jiang H, Mehra R. Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology. Med Oncol. 2015 Nov; 32(11):249. PMID: 26442515.
      View in: PubMed
    98. Johnson SB, Jackson WC, Murgic J, Feng F, Hamstra DA. Time to Nadir PSA: Of Popes and PSA--The Immortality Bias. Am J Clin Oncol. 2015 Oct; 38(5):465-71. PMID: 24064749.
      View in: PubMed
    99. Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Feng F, Martin NE, Efstathiou JA, Choueiri TK, Pomerantz MM, Sweeney CJ, Trinh QD, Vander Heiden MG, Nguyen PL. Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU Int. 2016 Aug; 118(2):279-85. PMID: 26235660.
      View in: PubMed
    100. Mahal BA, Muralidhar V, Chen YW, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Yu JB, Feng F, Trinh QD, Nguyen PL. Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? BJU Int. 2016 Jul; 118(1):95-101. PMID: 26207642.
      View in: PubMed
    101. Evans JR, Zhao S, Daignault S, Sanda MG, Michalski J, Sandler HM, Kuban DA, Ciezki J, Kaplan ID, Zietman AL, Hembroff L, Feng F, Suy S, Skolarus TA, McLaughlin PW, Wei JT, Dunn RL, Finkelstein SE, Mantz CA, Collins SP, Hamstra DA. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol. 2015 Aug; 116(2):179-84. PMID: 26276528.
      View in: PubMed
    102. Jackson WC, Johnson SB, Feng F, Hamstra DA. Salvage radiation therapy improves metastasis-free survival for clinically aggressive and indolent prostate cancer recurrences after radical prostatectomy. Am J Clin Oncol. 2015 Aug; 38(4):367-72. PMID: 23822986.
      View in: PubMed
    103. Muralidhar V, Chen MH, Reznor G, Moran BJ, Braccioforte MH, Beard CJ, Feng F, Hoffman KE, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4):828-35. PMID: 26530751.
      View in: PubMed
    104. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng F, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Sboner A, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM. Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 2015 Jul 16; 162(2):454. PMID: 28843286.
      View in: PubMed
    105. Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, Magee MS, Snook AE, Zhu Z, Den RB, Birbe RC, Gomella LG, Graham NA, Vashisht AA, Wohlschlegel JA, Graeber TG, Karnes RJ, Takhar M, Davicioni E, Tomlins SA, Abate-Shen C, Sharifi N, Witte ON, Feng F, Knudsen KE. DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. Cancer Cell. 2015 Jul 13; 28(1):97-113. PMID: 26175416; PMCID: PMC4531387.
    106. Nguyen PL, Shin H, Yousefi K, Thompson DJ, Hornberger J, Hyatt AS, Badani KK, Morgan TM, Feng F. Impact of a Genomic Classifier of Metastatic Risk on Postprostatectomy Treatment Recommendations by Radiation Oncologists and Urologists. Urology. 2015 Jul; 86(1):35-40. PMID: 26142578.
      View in: PubMed
    107. Feng F, de Bono JS, Rubin MA, Knudsen KE. Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. Mol Cell. 2015 Jun 18; 58(6):925-34. PMID: 26091341; PMCID: PMC4487541.
    108. Zaslavsky AB, Gloeckner-Kalousek A, Adams M, Putluri N, Venghatakrishnan H, Li H, Morgan TM, Feng F, Tewari M, Sreekumar A, Palapattu GS. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling. Neoplasia. 2015 Jun; 17(6):490-6. PMID: 26152357; PMCID: PMC4719002.
    109. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng F, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM. Integrative clinical genomics of advanced prostate cancer. Cell. 2015 May 21; 161(5):1215-1228. PMID: 26000489; PMCID: PMC4484602.
    110. Jackson WC, Schipper MJ, Johnson SB, Foster C, Li D, Sandler HM, Palapattu GS, Hamstra DA, Feng F. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol. 2016 Jan; 69(1):50-7. PMID: 26004800.
      View in: PubMed
    111. Zhao SG, Shilkrut M, Speers C, Liu M, Wilder-Romans K, Lawrence TS, Pierce LJ, Feng F. Development and validation of a novel platform-independent metastasis signature in human breast cancer. PLoS One. 2015; 10(5):e0126631. PMID: 25974184; PMCID: PMC4431866.
    112. Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng F. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Eur Urol. 2015 Oct; 68(4):555-67. PMID: 25964175; PMCID: PMC4562381 [Available on 10/01/16].
    113. Augello MA, Berman-Booty LD, Carr R, Yoshida A, Dean JL, Schiewer MJ, Feng F, Tomlins SA, Gao E, Koch WJ, Benovic JL, Diehl JA, Knudsen KE. Consequence of the tumor-associated conversion to cyclin D1b. EMBO Mol Med. 2015 May; 7(5):628-47. PMID: 25787974; PMCID: PMC4492821.
    114. Liss AL, Abu-Isa EI, Jawad MS, Feng F, Vance SM, Winfield RJ, Narayana V, Sandler HM, McLaughlin PW, Hamstra DA. Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: The impact of Gleason pattern 5. Brachytherapy. 2015 Jul-Aug; 14(4):502-10. PMID: 25911994.
      View in: PubMed
    115. Speers C, Zhao S, Liu M, Bartelink H, Pierce LJ, Feng F. Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer. Clin Cancer Res. 2015 Aug 15; 21(16):3667-77. PMID: 25904749.
      View in: PubMed
    116. Koloff ZB, Hamstra DA, Wei JT, Montgomery JS, Tomlins SA, Wu AJ, Morgan TM, Siddiqui J, Paich K, Chinnaiyan AM, Feng F, Weizer AZ, Kunju LP, Hollenbeck BK, Miller DC, Palapattu GS, Mehra R. Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series. Asian J Urol. 2015 Jan; 2(1):53-58. PMID: 29264120.
      View in: PubMed
    117. Vainshtein JM, Moon DH, Feng F, Chepeha DB, Eisbruch A, Stenmark MH. Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2015 Apr 01; 91(5):925-33. PMID: 25832685; PMCID: PMC4384167.
    118. Hovelson DH, McDaniel AS, Cani AK, Johnson B, Rhodes K, Williams PD, Bandla S, Bien G, Choppa P, Hyland F, Gottimukkala R, Liu G, Manivannan M, Schageman J, Ballesteros-Villagrana E, Grasso CS, Quist MJ, Yadati V, Amin A, Siddiqui J, Betz BL, Knudsen KE, Cooney KA, Feng F, Roh MH, Nelson PS, Liu CJ, Beer DG, Wyngaard P, Chinnaiyan AM, Sadis S, Rhodes DR, Tomlins SA. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia. 2015 Apr; 17(4):385-99. PMID: 25925381; PMCID: PMC4415141.
    119. Malik R, Khan AP, Asangani IA, Cieslik M, Prensner JR, Wang X, Iyer MK, Jiang X, Borkin D, Escara-Wilke J, Stender R, Wu YM, Niknafs YS, Jing X, Qiao Y, Palanisamy N, Kunju LP, Krishnamurthy PM, Yocum AK, Mellacheruvu D, Nesvizhskii AI, Cao X, Dhanasekaran SM, Feng F, Grembecka J, Cierpicki T, Chinnaiyan AM. Targeting the MLL complex in castration-resistant prostate cancer. Nat Med. 2015 Apr; 21(4):344-52. PMID: 25822367; PMCID: PMC4390530.
    120. Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng F, Dicker AP, Lallas CD, Gomella LG, Davicioni E, Karnes RJ. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol. 2015 Mar 10; 33(8):944-51. PMID: 25667284; PMCID: PMC4884273.
    121. Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, Poliakov A, Cao X, Dhanasekaran SM, Wu YM, Robinson DR, Beer DG, Feng F, Iyer HK, Chinnaiyan AM. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015 Mar; 47(3):199-208. PMID: 25599403; PMCID: PMC4417758.
    122. Warrick JI, Hovelson DH, Amin A, Liu CJ, Cani AK, McDaniel AS, Yadati V, Quist MJ, Weizer AZ, Brenner JC, Feng F, Mehra R, Grasso CS, Tomlins SA. Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma. Virchows Arch. 2015 Mar; 466(3):297-311. PMID: 25502898; PMCID: PMC4936404.
    123. Morgan TM, Feng F. Editorial comment. Urology. 2014 Dec; 84(6):1432-3. PMID: 25432833.
      View in: PubMed
    124. Mehra R, Shi Y, Udager AM, Prensner JR, Sahu A, Iyer MK, Siddiqui J, Cao X, Wei J, Jiang H, Feng F, Chinnaiyan AM. A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer. Neoplasia. 2014 Dec; 16(12):1121-7. PMID: 25499224; PMCID: PMC4309259.
    125. Foster CC, Jackson WC, Foster BC, Johnson SB, Feng F, Hamstra DA. Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy. Radiat Oncol. 2014 Nov 26; 9:245. PMID: 25424123; PMCID: PMC4255426.
    126. Prensner JR, Chen W, Han S, Iyer MK, Cao Q, Kothari V, Evans JR, Knudsen KE, Paulsen MT, Ljungman M, Lawrence TS, Chinnaiyan AM, Feng F. The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. Neoplasia. 2014 Nov; 16(11):900-8. PMID: 25425964; PMCID: PMC4240923.
    127. Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, Klein EA, Jenkins RB, Chinnaiyan AM, Feng F. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol. 2014 Dec; 15(13):1469-80. PMID: 25456366.
      View in: PubMed
    128. Cuneo KC, Chenevert TL, Ben-Josef E, Feng MU, Greenson JK, Hussain HK, Simeone DM, Schipper MJ, Anderson MA, Zalupski MM, Al-Hawary M, Galban CJ, Rehemtulla A, Feng F, Lawrence TS, Ross BD. A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Transl Oncol. 2014 Oct; 7(5):644-9. PMID: 25389460; PMCID: PMC4225651.
    129. Pollack A, Dignam JJ, Diaz DA, Wu Q, Stoyanova R, Bae K, Dicker AP, Sandler H, Hanks GE, Feng F. A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02. Clin Cancer Res. 2014 Dec 15; 20(24):6379-88. PMID: 25294917; PMCID: PMC4299458.
    130. Feng F, Speers C, Liu M, Jackson WC, Moon D, Rinkinen J, Wilder-Romans K, Jagsi R, Pierce LJ. Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer. Breast Cancer Res Treat. 2014 Aug; 147(1):81-94. PMID: 25104443.
      View in: PubMed
    131. Malik R, Patel L, Prensner JR, Shi Y, Iyer MK, Subramaniyan S, Carley A, Niknafs YS, Sahu A, Han S, Ma T, Liu M, Asangani IA, Jing X, Cao X, Dhanasekaran SM, Robinson DR, Feng F, Chinnaiyan AM. The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Mol Cancer Res. 2014 Aug; 12(8):1081-7. PMID: 25030374; PMCID: PMC4135019.
    132. Popovtzer A, Ibrahim M, Tatro D, Feng F, Ten Haken RK, Eisbruch A. MRI to delineate the gross tumor volume of nasopharyngeal cancers: which sequences and planes should be used? Radiol Oncol. 2014 Sep; 48(3):323-30. PMID: 25177248; PMCID: PMC4110090.
    133. Den RB, Feng F, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD, Gomella LG, Kelly WK, Birbe RC, McCue PA, Ghadessi M, Yousefi K, Davicioni E, Knudsen KE, Dicker AP. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2014 Aug 01; 89(5):1038-46. PMID: 25035207; PMCID: PMC4432840.
    134. Feng F, Brenner JC, Hussain M, Chinnaiyan AM. Molecular pathways: targeting ETS gene fusions in cancer. Clin Cancer Res. 2014 Sep 01; 20(17):4442-8. PMID: 24958807; PMCID: PMC4155001.
    135. Kozminski MA, Palapattu GS, Mehra R, Montgomery JS, Weizer AZ, Skolarus TA, Hollenbeck BK, Miller DC, He C, Tomlins S, Montie JE, Feng F, Wood DP, Kunju LP, Morgan TM. Understanding the relationship between tumor size, gland size, and disease aggressiveness in men with prostate cancer. Urology. 2014 Aug; 84(2):373-8. PMID: 24958484.
      View in: PubMed
    136. Zhao S, Chang SL, Linderman JJ, Feng F, Luker GD. A Comprehensive Analysis of CXCL12 Isoforms in Breast Cancer1,2. Transl Oncol. 2014 May 13. PMID: 24836649.
      View in: PubMed
    137. Vainshtein JM, Griffith KA, Feng F, Vineberg KA, Chepeha DB, Eisbruch A. Patient-reported voice and speech outcomes after whole-neck intensity modulated radiation therapy and chemotherapy for oropharyngeal cancer: prospective longitudinal study. Int J Radiat Oncol Biol Phys. 2014 Aug 01; 89(5):973-80. PMID: 24803039.
      View in: PubMed
    138. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng F, Chinnaiyan AM. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014 Jun 12; 510(7504):278-82. PMID: 24759320; PMCID: PMC4075966.
    139. Prensner JR, Sahu A, Iyer MK, Malik R, Chandler B, Asangani IA, Poliakov A, Vergara IA, Alshalalfa M, Jenkins RB, Davicioni E, Feng F, Chinnaiyan AM. The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget. 2014 Mar 30; 5(6):1434-8. PMID: 24727738; PMCID: PMC4039221.
    140. Johnson S, Jackson W, Speers C, Feng F, Hamstra D. A comprehensive assessment of the prognostic utility of the Stephenson nomogram for salvage radiation therapy postprostatectomy. Pract Radiat Oncol. 2014 Nov-Dec; 4(6):422-9. PMID: 25407865.
      View in: PubMed
    141. Stenmark MH, McHugh JB, Schipper M, Walline HM, Komarck C, Feng F, Worden FP, Wolf GT, Chepeha DB, Prince ME, Bradford CR, Mukherji SK, Eisbruch A, Carey TE. Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. Int J Radiat Oncol Biol Phys. 2014 Mar 01; 88(3):580-8. PMID: 24521676; PMCID: PMC3989890.
    142. Stenmark MH, Conlon AS, Johnson S, Daignault S, Litzenberg D, Marsh R, Ritter T, Vance S, Kazzi N, Feng F, Sandler H, Sanda MG, Hamstra DA. Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer. Radiother Oncol. 2014 Feb; 110(2):291-7. PMID: 24507766.
      View in: PubMed
    143. Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng F. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 2014 Mar 15; 74(6):1651-60. PMID: 24473064; PMCID: PMC4009928.
    144. Cao Q, Wang X, Zhao M, Yang R, Malik R, Qiao Y, Poliakov A, Yocum AK, Li Y, Chen W, Cao X, Jiang X, Dahiya A, Harris C, Feng F, Kalantry S, Qin ZS, Dhanasekaran SM, Chinnaiyan AM. The central role of EED in the orchestration of polycomb group complexes. Nat Commun. 2014; 5:3127. PMID: 24457600; PMCID: PMC4073494.
    145. Farjam R, Tsien CI, Feng F, Gomez-Hassan D, Hayman JA, Lawrence TS, Cao Y. Investigation of the diffusion abnormality index as a new imaging biomarker for early assessment of brain tumor response to radiation therapy. Neuro Oncol. 2014 Jan; 16(1):131-9. PMID: 24327584; PMCID: PMC3870818.
    146. Jackson W, Alexander N, Schipper M, Fig L, Feng F, Jolly S. Characterization of changes in total body composition for patients with head and neck cancer undergoing chemoradiotherapy using dual-energy x-ray absorptiometry. Head Neck. 2014 Sep; 36(9):1356-62. PMID: 23970480.
      View in: PubMed
    147. Han S, Brenner JC, Sabolch A, Jackson W, Speers C, Wilder-Romans K, Knudsen KE, Lawrence TS, Chinnaiyan AM, Feng F. Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. Neoplasia. 2013 Oct; 15(10):1207-17. PMID: 24204199; PMCID: PMC3819636.
    148. Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, Jenkins RB, Triche TJ, Malik R, Bedenis R, McGregor N, Ma T, Chen W, Han S, Jing X, Cao X, Wang X, Chandler B, Yan W, Siddiqui J, Kunju LP, Dhanasekaran SM, Pienta KJ, Feng F, Chinnaiyan AM. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet. 2013 Nov; 45(11):1392-8. PMID: 24076601; PMCID: PMC3812362.
    149. Goodwin JF, Schiewer MJ, Dean JL, Schrecengost RS, de Leeuw R, Han S, Ma T, Den RB, Dicker AP, Feng F, Knudsen KE. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov. 2013 Nov; 3(11):1254-71. PMID: 24027197; PMCID: PMC3823813.
    150. Johnson SB, Hamstra DA, Jackson WC, Zhou J, Foster B, Foster C, Song Y, Li D, Palapattu GS, Kunju L, Mehra R, Sandler H, Feng F. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Oct 01; 87(2):275-81. PMID: 23886418.
      View in: PubMed
    151. Jackson WC, Johnson SB, Foster B, Foster C, Li D, Song Y, Vainshtein J, Zhou J, Hamstra DA, Feng F. Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):99-107. PMID: 24890350.
      View in: PubMed
    152. Jackson WC, Johnson SB, Li D, Foster C, Foster B, Song Y, Schipper M, Shilkrut M, Sandler HM, Morgan TM, Palapattu GS, Hamstra DA, Feng F. A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy. Radiat Oncol. 2013 Jul 08; 8:170. PMID: 23835115; PMCID: PMC3718717.
    153. Jackson W, Hamstra DA, Johnson S, Zhou J, Foster B, Foster C, Li D, Song Y, Palapattu GS, Kunju LP, Mehra R, Feng F. Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. Cancer. 2013 Sep 15; 119(18):3287-94. PMID: 23821578.
      View in: PubMed
    154. Dobrosotskaya IY, Bellile E, Spector ME, Kumar B, Feng F, Eisbruch A, Wolf GT, Prince ME, Moyer JS, Teknos T, Chepeha DB, Walline HM, McHugh JB, Cordell KG, Ward PD, Byrd S, Maxwell JH, Urba S, Bradford CR, Carey TE, Worden FP. Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx. Head Neck. 2014 May; 36(5):617-23. PMID: 23596055; PMCID: PMC4205960.
    155. Hunter KU, Lee OE, Lyden TH, Haxer MJ, Feng F, Schipper M, Worden F, Prince ME, McLean SA, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A. Aspiration pneumonia after chemo-intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors. Head Neck. 2014 Jan; 36(1):120-5. PMID: 23729173; PMCID: PMC4144677.
    156. Shilkrut M, McLaughlin PW, Merrick GS, Vainshtein JM, Feng F, Hamstra DA. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):721-8. PMID: 23664325.
      View in: PubMed
    157. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, Cheng AJ, Kunju LP, Siddiqui J, Tomlins SA, Wyngaard P, Sadis S, Roychowdhury S, Hussain MH, Feng F, Zalupski MM, Talpaz M, Pienta KJ, Rhodes DR, Robinson DR, Chinnaiyan AM. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013 Jun; 3(6):636-47. PMID: 23558953; PMCID: PMC3694764.
    158. Johnson S, Jackson W, Li D, Song Y, Foster C, Foster B, Zhou J, Vainshtein J, Feng F, Hamstra D. The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Jul 01; 86(3):554-61. PMID: 23561650.
      View in: PubMed
    159. White NM, Feng F, Maher CA. Recurrent rearrangements in prostate cancer: causes and therapeutic potential. Curr Drug Targets. 2013 Apr; 14(4):450-9. PMID: 23410129; PMCID: PMC3733264.
    160. Feng F, Blas K, Olson K, Stenmark M, Sandler H, Hamstra DA. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2013 May 01; 86(1):64-71. PMID: 23462420.
      View in: PubMed
    161. Augello MA, Burd CJ, Birbe R, McNair C, Ertel A, Magee MS, Frigo DE, Wilder-Romans K, Shilkrut M, Han S, Jernigan DL, Dean JL, Fatatis A, McDonnell DP, Visakorpi T, Feng F, Knudsen KE. Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. J Clin Invest. 2013 Jan; 123(1):493-508. PMID: 23257359; PMCID: PMC3533295.
    162. Hamstra DA, Stenmark MH, Ritter T, Litzenberg D, Jackson W, Johnson S, Albrecht-Unger L, Donaghy A, Phelps L, Blas K, Halverson S, Marsh R, Olson K, Feng F. Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Apr 01; 85(5):1246-53. PMID: 23265567.
      View in: PubMed
    163. Farjam R, Tsien CI, Feng F, Gomez-Hassan D, Hayman JA, Lawrence TS, Cao Y. Physiological imaging-defined, response-driven subvolumes of a tumor. Int J Radiat Oncol Biol Phys. 2013 Apr 01; 85(5):1383-90. PMID: 23257692.
      View in: PubMed
    164. Grivas PD, Davenport M, Montie JE, Kunju LP, Feng F, Weizer AZ. Urethral cancer. Hematol Oncol Clin North Am. 2012 Dec; 26(6):1291-314. PMID: 23116581.
      View in: PubMed
    165. Chang SS, Dinney CP, Donat SM, Dahm P, Gore JL, Lotan Y, Parekh DJ, Solit DB, O'Donnell PH, Feng F, Hansel D, Milowsky MI. 12th Annual meeting of the Society of Urologic Oncology (SUO) bladder cancer sessions I and II summary report. Urol Oncol. 2012 Nov-Dec; 30(6):944-7. PMID: 23218073.
      View in: PubMed
    166. Hunter KU, Schipper M, Feng F, Lyden T, Haxer M, Murdoch-Kinch CA, Cornwall B, Lee CS, Chepeha DB, Eisbruch A. Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):935-40. PMID: 23040224; PMCID: PMC3556374.
    167. Shilkrut M, Feng F, Hamstra DA. General commentary to the "management of biochemical recurrence after primary localized therapy for prostate cancer" by darwish o. M. And raj g. V. Front Oncol. 2012; 2:126. PMID: 23061043; PMCID: PMC3459002.
    168. Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM, McCue P, Gomella LG, Raj GV, Dicker AP, Brody JR, Pascal JM, Centenera MM, Butler LM, Tilley WD, Feng F, Knudsen KE. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012 Dec; 2(12):1134-49. PMID: 22993403; PMCID: PMC3519969.
    169. Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng F, Hamstra DA. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. Cancer. 2013 Feb 01; 119(3):681-90. PMID: 22893254.
      View in: PubMed
    170. Murgic J, Stenmark MH, Halverson S, Blas K, Feng F, Hamstra DA. The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for prostate cancer. Radiat Oncol. 2012 Aug 01; 7:127. PMID: 22852797; PMCID: PMC3484035.
    171. Sabolch A, Feng M, Griffith K, Rzasa C, Gadzala L, Feng F, Biermann JS, Chugh R, Ray M, Ben-Josef E. Risk factors for local recurrence and metastasis in soft tissue sarcomas of the extremity. Am J Clin Oncol. 2012 Apr; 35(2):151-7. PMID: 21336091.
      View in: PubMed
    172. Brenner JC, Feng F, Han S, Patel S, Goyal SV, Bou-Maroun LM, Liu M, Lonigro R, Prensner JR, Tomlins SA, Chinnaiyan AM. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 2012 Apr 01; 72(7):1608-13. PMID: 22287547; PMCID: PMC3319786.
    173. Pak D, Vineberg K, Feng F, Ten Haken RK, Eisbruch A. Lhermitte sign after chemo-IMRT of head-and-neck cancer: incidence, doses, and potential mechanisms. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1528-33. PMID: 22284690; PMCID: PMC3481166.
    174. Hunter KU, Feng F, Griffith KA, Francis IR, Lawrence TS, Desai S, Murphy JD, Zalupski MM, Ben-Josef E. Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):921-6. PMID: 22208966.
      View in: PubMed
    175. Vance SM, Stenmark MH, Blas K, Halverson S, Hamstra DA, Feng F. Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):940-6. PMID: 22056069.
      View in: PubMed
    176. Little M, Schipper M, Feng F, Vineberg K, Cornwall C, Murdoch-Kinch CA, Eisbruch A. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):1007-14. PMID: 22056067; PMCID: PMC3288420.
    177. Kapadia NS, Olson K, Sandler HM, Feng F, Hamstra DA. Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancer. Cancer. 2012 Apr 15; 118(8):2059-68. PMID: 22009287.
      View in: PubMed
    178. Feng F, Qian Y, Stenmark MH, Halverson S, Blas K, Vance S, Sandler HM, Hamstra DA. Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e361-7. PMID: 21820250.
      View in: PubMed
    179. Halverson S, Schipper M, Blas K, Lee V, Sabolch A, Olson K, Sandler HM, Feng F, Hamstra DA. The Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radiation therapy: evaluation and optimization in patients at higher risk of relapse. Radiother Oncol. 2011 Dec; 101(3):513-20. PMID: 21703711.
      View in: PubMed
    180. Stenmark MH, Blas K, Halverson S, Sandler HM, Feng F, Hamstra DA. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e335-44. PMID: 21645976.
      View in: PubMed
    181. Eisbruch A, Kim HM, Feng F, Lyden TH, Haxer MJ, Feng M, Worden FP, Bradford CR, Prince ME, Moyer JS, Wolf GT, Chepeha DB, Ten Haken RK. Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):e93-9. PMID: 21592678; PMCID: PMC3158965.
    182. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng F, Chinnaiyan AM. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 2011 May 17; 19(5):664-78. PMID: 21575865; PMCID: PMC3113473.
    183. Sabolch A, Feng F, Daignault-Newton S, Halverson S, Blas K, Phelps L, Olson KB, Sandler HM, Hamstra DA. Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e351-60. PMID: 21493015.
      View in: PubMed
    184. Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X, Li Y, Wang X, Feng F, Pienta KJ, Varambally S, Chinnaiyan AM. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med. 2011 Mar 02; 3(72):72ra17. PMID: 21368222; PMCID: PMC3211047.
    185. Qian Y, Feng F, Halverson S, Blas K, Sandler HM, Hamstra DA. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):e135-42. PMID: 21345617.
      View in: PubMed
    186. Gluck I, Griffith KA, Biermann JS, Feng F, Lucas DR, Ben-Josef E. Role of radiotherapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys. 2011 Jul 01; 80(3):787-92. PMID: 20615622.
      View in: PubMed
    187. Maxwell JH, Kumar B, Feng F, McHugh JB, Cordell KG, Eisbruch A, Worden FP, Wolf GT, Prince ME, Moyer JS, Teknos TN, Chepeha DB, Stoerker J, Walline H, Carey TE, Bradford CR. HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans. Head Neck. 2010 May; 32(5):562-7. PMID: 19757421; PMCID: PMC2855405.
    188. Feng F, Kim HM, Lyden TH, Haxer MJ, Worden FP, Feng M, Moyer JS, Prince ME, Carey TE, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol. 2010 Jun 01; 28(16):2732-8. PMID: 20421546; PMCID: PMC2881852.
    189. Rancati T, Schwarz M, Allen AM, Feng F, Popovtzer A, Mittal B, Eisbruch A. Radiation dose-volume effects in the larynx and pharynx. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3 Suppl):S64-9. PMID: 20171520; PMCID: PMC2833104.
    190. Maxwell JH, Kumar B, Feng F, Worden FP, Lee JS, Eisbruch A, Wolf GT, Prince ME, Moyer JS, Teknos TN, Chepeha DB, McHugh JB, Urba SG, Stoerker J, Walline HM, Kurnit DM, Cordell KG, Davis SJ, Ward PD, Bradford CR, Carey TE. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res. 2010 Feb 15; 16(4):1226-35. PMID: 20145161; PMCID: PMC2822887.
    191. Gluck I, Feng F, Lyden T, Haxer M, Worden F, Chepeha DB, Eisbruch A. Evaluating and reporting dysphagia in trials of chemoirradiation for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010 Jul 01; 77(3):727-33. PMID: 19783380; PMCID: PMC2878868.
    192. Popovtzer A, Cao Y, Feng F, Eisbruch A. Anatomical changes in the pharyngeal constrictors after chemo-irradiation of head and neck cancer and their dose-effect relationships: MRI-based study. Radiother Oncol. 2009 Dec; 93(3):510-5. PMID: 19520446; PMCID: PMC2787803.
    193. Feng F, Ben-Josef E. Radiation therapy improves survival in patients with pancreatic adenocarcinoma. Nat Clin Pract Oncol. 2008 Aug; 5(8):434-5. PMID: 18594497.
      View in: PubMed
    194. Wang G, Jacobson JA, Feng F, Girish G, Caoili EM, Brandon C. Sonography of wrist ganglion cysts: variable and noncystic appearances. J Ultrasound Med. 2007 Oct; 26(10):1323-8; quiz 1330-1. PMID: 17901135.
      View in: PubMed
    195. Lopez CA, Feng F, Herman JM, Nyati MK, Lawrence TS, Ljungman M. Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation. Int J Radiat Oncol Biol Phys. 2007 Sep 01; 69(1):214-20. PMID: 17707275.
      View in: PubMed
    196. Feng F, Kim HM, Lyden TH, Haxer MJ, Feng M, Worden FP, Chepeha DB, Eisbruch A. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys. 2007 Aug 01; 68(5):1289-98. PMID: 17560051.
      View in: PubMed
    197. Feng F, Lopez CA, Normolle DP, Varambally S, Li X, Chun PY, Davis MA, Lawrence TS, Nyati MK. Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. Clin Cancer Res. 2007 Apr 15; 13(8):2512-8. PMID: 17438112.
      View in: PubMed
    198. Eisbruch A, Levendag PC, Feng F, Teguh D, Lyden T, Schmitz PI, Haxer M, Noever I, Chepeha DB, Heijmen BJ. Can IMRT or brachytherapy reduce dysphagia associated with chemoradiotherapy of head and neck cancer? The Michigan and Rotterdam experiences. Int J Radiat Oncol Biol Phys. 2007; 69(2 Suppl):S40-2. PMID: 17848291; PMCID: PMC2801073.
    199. Nyati MK, Feng F, Maheshwari D, Varambally S, Zielske SP, Ahsan A, Chun PY, Arora VA, Davis MA, Jung M, Ljungman M, Canman CE, Chinnaiyan AM, Lawrence TS. Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation. Cancer Res. 2006 Dec 15; 66(24):11554-9. PMID: 17178844.
      View in: PubMed
    200. Nyati MK, Morgan MA, Feng F, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer. 2006 11; 6(11):876-85. PMID: 17036041.
      View in: PubMed
    201. Nyati MK, Feng F, Kanade VD, Nayak R. Chloroquine treatment increases detection of 5-fluorouracil-induced apoptosis index in vivo. Mol Imaging. 2006 Jul; 5(3):148-52. PMID: 16954029.
      View in: PubMed
    202. Chun PY, Feng F, Scheurer AM, Davis MA, Lawrence TS, Nyati MK. Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res. 2006 Jan 15; 66(2):981-8. PMID: 16424033.
      View in: PubMed